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Liver metastasis is a frequent occurrence in patients with breast cancer; however, the available treatments are
limited and ineffective. While liver-specific homing of breast cancer cells is an important feature of metastasis, the
formation of liver metastases is not random. Indeed, breast cancer cell factors contribute to the liver microenvironment.
Major breakthroughs have been achieved recently in understanding breast cancer liver metastasis (BCLM). The process
of liver metastasis consists of multiple steps and involves various factors from breast cancer cells and the liver
microenvironment. A further understanding of the roles of breast cancer cells and the liver microenvironment is crucial
to guide future work in clinical treatments. In this review we discuss the contribution of breast cancer cells and the liver
microenvironment to liver metastasis, with the aim to improve therapeutic efficacy for patients with BCLM.
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Breast cancer is the leading cause of cancer-related
deaths in female patients worldwide [1]. Breast cancer
has been divided into at least five subtypes, as follows:
luminal A, luminal B, human epithelial growth receptor
type 2 (HER-2), basal-like, and claudin-low [2]. It has
been reported that the 5-year survival rate for primary
breast cancer is 99%. Nevertheless, approximately one-third
of breast cancer patients will present with distant non-
nodal metastases, and the 5-year survival rate decreases to
23% once distant metastases have developed [3]. Breast
cancer mainly metastasizes to the bony skeleton, lungs,
liver, and brain via the circulation; the liver is a common
metastatic site for solid cancers and represents the third
most common site for breast cancer [4]. If breast cancer
liver metastasis (BCLM) is left untreated, the survival time
is only 4–8 months [5]. Current treatments for BCLM
are based on a strategy of systemic chemotherapy,
endocrine- or HER2-targeted therapy (depending on
estrogen receptor [ER], progesterone receptor [PR], and
HER-2 status), and palliative therapy, such as radiation
[6,7]. Nevertheless, it is important to note that some
patients exhibit de novo resistance or eventually become* Correspondence: cxjzu@hotmail.com
2Department of General Surgery, Institute of Minimally Invasive Surgery, Sir
Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou,
Zhejiang 310016, China
Full list of author information is available at the end of the article
© 2015 Ma et al.; licensee BioMed Central. Thi
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.resistant to endocrine therapy [8]. Moreover, a poor
response to chemotherapy accounts for much of the high
mortality in patients with BCLM [9].
The formation and growth of breast cancer cells in the
liver is a complex process. The most widely accepted
model for metastasis is the “seed and soil” hypothesis,
which was postulated by Stephen Paget in 1889 [10].
Paget speculated that organ metastases form merely
when the seed (disseminated tumor cells) and soil
(secondary organ) are compatible [10,11]. Semenza
separated the process of blood vessel metastasis of
breast cancer into the following steps: intravasation,
circulation, margination, extravasation, and colonization
[12]. The molecular mechanisms underlying breast
cancer metastasis have been reported for breast cancer
dissemination to the lungs and bone [13-20]; however, the
molecular mechanisms for liver metastasis have not
been completely described [21]. Moreover, the hepatic
microenvironment and liver sinusoidal structure is crucial
for the initial arrest of breast cancer and progression within
the liver. Thus, exploring the mechanisms underlying liver
metastasis in breast cancer patients is essential for
developing more effective therapies. A further understand-
ing of the roles of breast cancer cells and the liver
microenvironment in early breast cancer metastasis is
crucial for the development of effective BCLM therapies
[10,22]. Therefore, this review will discuss the moleculars is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to guide future work in clinical treatments.
Factors associated with breast cancer cell
metastasis to the liver
Inflammatory factors
Several studies have shown that the inflammatory
response correlates with the liver metastatic potential of
some tumors [23,24]. The inflammatory factor, TNF-α,
can trigger the expression of E-selectin in endothelial
cells, including liver sinusoidal endothelium cells [25,26].
It has been reported that breast cancer cells have the ability
to initiate an inflammatory cascade, which increases adhe-
siveness to liver sinusoidal endothelium cells, similar to
that induced by colorectal and lung cancers [27]. Although
the process of tumor cell attachment to the endothelium
during metastasis is multifactorial, the production of
TNF-α-induced endothelial E-selectin in tumor cells
appears to be a key step in the BCLM process [28].
Asgeirsson et al. [29] reported that induction of IL-6
decreased cell adhesion in three breast cancer cell lines,
and was associated with reduced E-cadherin expression.
Moreover, patients with breast cancer liver metastases had
significantly higher IL-6 levels. Therefore, it appears that
breast cancer cells create a pro-inflammatory microenvir-
onment which triggers adhesion and invasion of tumor
cells into the liver by secreting a number of cytokines.
Chemokines and chemokine receptors
Breast cancer cells express several chemokine receptors
that initiate liver metastasis, of which C-X-C Chemokine
Receptor type 4 (CXCR4) is the most common. Moreover,
the ligand of CXCR4, stromal-derived factor 1-α (SDF-1,
CXCL12), is also highly expressed in the liver [30],
indicating that the CXCL12/CXCR4 interaction might
contribute to BCLM. It has also been reported that
CXCR4 plays an important role in modulating breast-
to-liver metastasis through integrin–adhesion-receptor
signaling [31]. The availability of chemokine receptors on
tumor cell surfaces, the presence of specific ligands within
the microenvironment of potential target organs, and the
suitability of the extracellular matrix (ECM) composition
appear to be required for successful extravasation of
breast cancer cells in the early metastatic process [32].
Furthermore, expression of CXCR4 increases the risk
of metastasis to the liver in patients with axillary
node-positive primary breast cancer [33]. In tumor-bearing
mice, CC chemokine ligand 2 (CCL2) neutralizing anti-
bodies inhibit the growth and liver metastases of primary
breast cancer by reducing cell proliferation, survival, and
tumor-associated macrophage (TAM) recruitment. These
results have also revealed that CCL2 can enhance primary
breast cancer liver metastasis in a TAM-dependent manner
[34]. Stormes et al. [35] strongly support the notion thatinhibition of tumor-derived CCL5 can inhibit the capability
of liver metastasis in breast cancer cells. Similar analyses
have shown that the release of CCL5 by cells of the tumor
microenvironment promotes the metastatic spread to the
liver of breast cancer cells [36]. Moreover, Mi et al. [37]
have demonstrated that induced mesenchymal stromal cells
(MSCs) produce CCL5, and significantly promote breast
cancer cell migration to the liver in vivo and in vitro. There-
fore, some chemokine receptors can enhance breast cancer
metastasis to the liver. Porter et al. [38] reported, however,
that many chemokines are lost in breast cancer, including
CXCL1, CXCL2, CXCL5, CXCL6, CXCL8, CXCL20,
CX3CL1, CCL2, and CCL7. Whether or not some of these
chemokines are involved in BCLM warrants further study.
Taken together, chemokines and their receptors are the
regulators involved in the process of BCLM.
Cell adhesion molecules
Cadherins
E-cadherin expression in liver metastatic sites is due
to loss of promoter methylation. Breast cancer cells
that re-express E-cadherin revert back to an epithelial
phenotype [39-42]. In primary cancer, the epithelial-to-
mesenchymal transition (EMT) of cancer cells contributes
to increased invasion and dissemination [43]. Once cancer
cells have seeded the metastatic site, a mesenchymal-to-
epithelial transition (MET) occurs, leading to the
colonization and growth of metastatic foci [44]. Expres-
sion of the cell adhesion molecule, E-cadherin, in breast
cancer cells can facilitate breast cancer cell adhesion to
hepatocytes for seeding in the liver [9,43]. Moreover, some
results have shown that breast cancer cells that express
E-cadherin are able to form liver metastases, while E-
cadherin-negative cancer cells merely form primary
tumors [45,46]. Intriguingly, Chao et al. [9] showed that
the liver microenvironment can induce breast cancer cells
to re-express E-cadherin and cause MET. This phenotypic
change has the potential to alter cell behavior, and thus
may be a critical step for cells to survive at metastatic sites
within the liver. Take together, these results suggest that
re-expression of E-cadherin, accompanied by a partial
MET in the liver, increases post-extravasation survival of
metastatic cancer cells and may help to elucidate why
chemotherapy commonly fails to treat BCLM.
Previous studies have shown that N-cadherin is up-
regulated in more invasive and less differentiated breast
cancer cell lines that lack E-cadherin expression [47,48].
The study by Hazan et al. [49] showed that breast cancer
expressing N-cadherin grew slower, on average, and the
two clones with the highest levels of N-cadherin formed
liver metastases in almost all mice injected with breast
cancer cells. In addition, N-cadherin activates a metastatic
signaling pathway coordinated by fibroblast growth factor
receptor (FGFR) and matrix metalloproteinase-9 (MMP-9)
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Thus, these studies provide a basis for N-cadherin-mediated
liver metastasis of breast cancer, whereas E-cadherin
suppresses liver metastases, and offer new insights into
the diagnostic or therapeutic applications for BCLM.Integrin complexes
Heterodimeric transmembrane receptors of the integrins
family are important components of the ECM. Eighteen
α-subunits and 8 β-subunits have been characterized
and form 24 different integrins [50], including laminin
(LN), collagen (Col), fibrinogen, and vitronectin (VN)
[51]. Each integrin heterodimer binds to a specific ligand
within the ECM. By using bidirectional “outside-in” and
“inside-out” signaling, integrin complexes regulate multiple
biological processes, such as adhesion, apoptosis, prolifera-
tion, differentiation, migration, invasion, and metastasis
[52]. It has been reported that use of an antagonist of α2β1
complexes can reduce the extravasation of colorectal
and hepatocellular carcinoma cell lines into the liver
and micrometastic sites [53]. Moreover, the functional
integrin complexes (fibronectin and collagen IV receptors)
are recruited, assembled, and thus increased on the cell
surface in liver metastatic breast cancer cells. Neutralizing
antibody targeting α5β1 or α2β1 complexes can block
claudin-2-mediated adhesion to fibronectin and type IV
collagen, and reduce the ability of breast cancer cells to
metastasize to the liver [54]. Therefore, α2β1 or α5β1
complexes can promote the ability of breast cancer
cells to metastasize to the liver, at least partially, via the
claudin-2 signaling pathway.Ig-SF
Epithelial cell adhesion molecule (EpCAM/CD326), also
a transmembrane protein, plays a variety of roles in cell
proliferation, adhesion, migration, and tissue maintenance
[55,56]. EpCAM is expressed at low levels in luminal
epithelial cells of benign breast tissues. Nevertheless,
EpCAM is overexpressed in many carcinomas, including
breast cancer; a recent study suggested that p53 dysfunc-
tion may serve to explain this phenomenon [57]. In
patients with node-positive primary breast cancer, elevated
EpCAM expression correlates with diminished overall
survival [58,59], suggesting that overexpression of EpCAM
promotes cancer progression and metastasis. Litvinov et al.
[60,61] also found that EpCAM can act as an antagonist
impairing E-cadherin function via disruption of the
α-catenin/F-actin link, and loosening tight cell-cell
adhesions. In addition, EpCAM is highly expressed in
MBCs, including the sites of liver metastases, compared
to unmatched, surgically resected primary breast cancers
[61]. Therefore, EpCAM might serve as a promising
therapeutic target for BCLM.CD44
It has been reported that cancer stem cells (CSCs)
within tumors have cancer-initiating potential and
metastatic capability [62]. High levels of CD44 expressed
by CSCs are believed to be involved in adhesion, invasion,
apoptosis resistance, and metastasis [63-65]. Moreover,
breast cancer cells expressing high levels of CD44 and low
levels of CD24 maintain stemness properties [62,66]. Erin
et al. [67] found that CD44 expression was highest in cells
that metastasized to the liver, and liver tropism of
breast cancer is driven by CSCs. In addition, it has
been demonstrated that serum CD44 v5 and v6 are
released by breast cancer cells and increased CD44 v6
serum levels are preferentially detected in patients
with liver metastases [68,69]. Furthermore, Ouhtit
et al. [70] showed that CD44 promotes breast tumor
invasion and metastasis to the liver. Together, high
levels of CD44 expressed by CSCs and breast cancer
cells are significantly correlated with BCLM.
Based on the above results, it appears that cell adhesion
molecules play important roles in BCLM (Table 1);
however, studies involving cell adhesion molecules
that effect BCLM is still limited, and uncovering the
mechanisms would provide novel therapeutic approaches
in drug design and cancer therapy.
Role of claudins
In normal epithelia, claudins are key transmembrane
proteins within the tight junction complex that participate
in homo- and hetero-typic interactions between adjacent
cells [71]. The roles of claudin proteins in breast cancer
progression are complicated, and claudin-2 expression is
down-regulated compared with normal tissues. Moreover,
decreased levels of claudin-2 are observed in high-grade
breast cancer, suggesting that claudin-2 plays a suppres-
sive role in breast cancer [72]. Moreover, Kimbung et al.
[73] reported that claudin-2 is a prognostic biomarker that
not only predicts the likelihood of a breast cancer recur-
rence, but more interestingly, the metastatic potential of
breast cancer to the liver. Furthermore, Tabariès et al.
[54,74] demonstrated that elevated levels of claudin-2
expression, or selection for pre-existing claudin-2-positive
breast cancer cells within liver metastases may serve to
enhance the survival of breast cancer cells by promoting
interactions between the tumor cell and resident hepato-
cytes. Claudin-2 mediates breast cancer metastasis to the
liver, at least partially, by enhancing adhesion to ECM
proteins, such as fibronectin and type IV collagen, which
are abundant in the liver. Immunohistochemical analyses
have shown that claudin-2 is detected in all liver metastases
and weakly expressed in primary human breast cancers.
Take together, these results revealed novel roles of
claudin-2 in promoting breast cancer adhesion to the
ECM and breast cancer metastasis to the liver.
Table 1 Cell adhesion molecules (CAMs) involved in breast cancer liver metastasis
CAM family Expression in primary cancer Role Expression in BCLM Role
Cadherins
E-cadherin ↓Breast cancer cells Adhesion, invasion, EMT ↑Breast cancer cells [9,43,45,46] MET
N-cadherin ↑Breast cancer cells, Angiogenesis, EMT ↑Breast cancer cells [49] MET
↑Endothelium cells
Integrin complexes
α2β1 ↓Breast cancer cells, Adhesion, migration,
invasion, angiogenesis
↑Breast cancer cells [54] liver metastasis,
tumor angiogenesis
↑Endothelium cells




EpCAM ↑Breast cancer cells Migration, invasion ↑Breast cancer cells [61] liver metastasis
CD44 ↓Breast cancer cells (CD44s); adhesion, invasion ↑Breast cancer cells [67,68] Liver metastasis
↑Breast cancer cells (CD44v3,
CD44v4, CD44v5, CD44v6)
Note: ↑, up-regulation; ↓, down-regulation; EMT, epithelial to mesenchymal transition; MET, mesenchymal to epithelial reverting transition.
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with poor prognosis and the breast cancer basal-like
subtype [75-77]. A recent study demonstrated that the
loss of claudin-4 and −7 promoted liver metastasis of
breast cancer cells in Balb-c mice [78]. We speculate
that the discrepant roles of claudin-4 with poor prognosis
in different studies might be due to different subtypes or
species. Intriguingly, a ‘claudin-low’ subtype of breast
cancer has recently been identified in primary human
breast cancers. This subtype possesses features similar to,
but distinct from the breast cancer basal subtype defined
previously [79]; the breast cancer claudin-low and basal
subtypes are functionally coupled by EMT characteristics,
enhanced cancer stem cell–like features, and resistance to
chemotherapy [80-84]. Nevertheless, the patterns of
expression of claudins in the claudin-low subtype of breast
cancer have not been described.
In summary, the above findings imply that claudin-2, −4,
and −7 are all necessary and sufficient for the ability of
breast cancer cells to colonize and grow in the liver.
It is important to delineate the mechanism underlying
preferential metastasis of breast cancer to the liver.
Breast cancer subtypes
It has been reported that five major subtypes of breast
cancer have different abilities to metastasize to distant
organs, and share pathways with the preferred metastatic
sites. Patients with bone relapses have the luminal
subtypes of breast cancer most frequently. The HER-2
subtype may metastasize to bone via processes that
differ from the luminal subtypes. Moreover, the basal
subtype often metastasizes to the brain and lungs.
However, it fails to reach statistical significance in patients
with liver relapse [85]. Rodriguez-Pinilla et al. [86] reportedthat the basal-like subtype metastasizes more frequently to
the lungs and other visceral organs, such as the brain and
liver, but no bone metastases were detected. Moreover,
recent studies [87-89] in patients from eastern Europe,
Asia, and the US have suggested a high incidence of brain
metastases arising from basal-like tumors (ER-/PR-/HER2-,
and usually identified as “triple-negative” breast cancer
[TNBC]) [90], but it has been reported that p53-negative
TNBC has an increased tendency to develop lung metasta-
ses [91]. Furthermore, Duan et al. [92] showed that the
breast cancer subtype is an independent prognostic
predictor for patients with breast cancer metastases to the
liver. Survival after liver metastases arising from TNBC is
21 months compared to 30, 32, and 41 months for patients
with the HER-2, luminal B, and luminal A subtypes; liver
metastases from TNBC has the worst prognosis. Therefore,
novel agents controlling liver metastases in patients with
TNBC are needed. Taken together, different subtypes of
breast cancer have preferred metastatic organs; however,
no conclusive evidence exists to mechanistically link any
specific subtype to BCLM development.
Factors associated with the liver
microenvironment
Hypoxia-inducible factor-regulated genes
Hypoxia-inducible factors (HIFs) activate the transcrip-
tion of target genes that are involved in many aspects
of breast cancer progression, such as angiogenesis,
metabolic reprogramming, local tissue invasion, and
metastasis [12,93]. It has been reported that HIFs not
only activate lysyl oxidase (LOX) directly to inhibit
liver metastases, but osteopontin (OPN), vascular
endothelial growth factor (VEGF), and TWIST promote
BCLM (Table 2). It has been suggested that some of the
Table 2 Hypoxia-inducible factor (HIF)-regulated genes in
breast cancer liver metastasis
Gene HIF regulation Role in BCLM
LOX [94] HIF-1 and HIF-2 Inhibition
OPN [37,69] HIF-1 (HIF-2 not tested) Promotion
Twist [95,116] HIF-1 (HIF-2 not tested) Promotion
VEGF [95] HIF-1 and HIF-2 Promotion
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BCLM [37,69,94,95].
LOX
LOX is an amine oxidase that contributes to the forma-
tion of the ECM. LOX is secreted by fibrinogenic cells
and residues in collagen and elastin to maintain the
structural stabilization of the ECM [96]. Of note, LOX
expression has paradoxical roles in tumor suppression
and tumor progression, depending on cellular location,
type, and transformation status [96-101]. Erler et al. [94]
proposed that hypoxia-induced LOX has a key function
in the metastasis of breast cancer cells. Although no
marked inhibition effects of LOX on primary breast
cancer growth was observed, Erler et al. [94] found
significant effects on growth in metastatic sites within
the liver. These data indicate that the effects of LOX on
cell adhesion, migration, invasion, and three-dimensional
growth are more crucial for liver metastatic growth
than primary breast cancers. This study may provide
mechanistic evidence for hypoxia-driven liver metastases
and support the therapeutic target of LOX in the preven-
tion and treatment of BCLM.
OPN
HIF-induced OPN is a secreted phosphoprotein func-
tioning as a cell attachment protein by binding two cell
adhesion molecules (αvβ3 integrin and CD44) [102-104].
It has been reported that OPN is overexpressed in
tumors and elevated serum OPN levels are associated
with advanced metastatic cancer [105-108]. Gain- and
loss-of-function assays have demonstrated the critical
role for OPN in tumor metastases of colon, liver, and
breast cancers [69]. Mi et al. [37] revealed that MSCs
extracted from metastatic sites exhibit significantly
increased expression of cancer-associated fibroblast
(CAF) markers, such as α-smooth muscle actin (α-SMA),
tenascin-c, CXCL12, and fibroblast-specific protein (FSP)-1.
OPN expression promotes tumor growth and metastasis by
activating the expression of CCL5, MMPs, and CAF in
MSCs. Thus, the transformation of MSCs to CAF can be
mediated by OPN in the tumor microenvironment. In
addition, the current study showed that the expression of
CAF markers was also significantly increased in the liver
metastases sites. These findings suggest a novel mechanismby which OPN affects BCLM by transforming MSCs
into a CAF.
VEGF and TWIST
Cancer cells express a number of angiogenic factors.
VEGFs are the key mediator of neovascularization in
tumors [109]. Inhibition of VEGF-A/VEGFR-2 and
VEGF-C/VEGFR-3 signals has been shown to suppress
breast cancer progression and lung metastases [110].
Chien et al. [111] found that inhibition of VEGFR/FGFR
kinases drastically reduce the formation of liver metastases
and decreased primary breast cancer growth. TWIST is a
basic helix-loop-helix transcription factor. TWIST
mainly regulates gastrulation and mesoderm specification
[112,113]. Recently, TWIST has been shown to play an
important role in mediating cancer metastasis [114,115].
TWIST is a downstream target of HIF-1 and has an
important role in metastatic phenotypes induced by
hypoxia or overexpression of HIF-1α in breast cancer
cell lines (MCF-7). HIF-1α promotes hypoxia-induced
breast cancer progression and metastasis through the
direct activation of TWIST expression [116].
In a previous report, inhibition of HIF-1α by 2-benzoyl-
3-phenyl-6, 7-dichloroquinoxaline 1, 4-dioxide (DCQ) was
shown to block VEGF secretion and invasion in MCF-7 and
led to the inhibition of TWIST expression in MDA-MB-
231. DCQ exhibits robust anti-tumor activity in MDA-MB-
231 breast cancer mouse xenografts. Also, DCQ reduces
metastatic dissemination to the liver, leading to prolonged
animal survival [95]. Therefore, HIF-1α can promote BCLM
throughVEGF and TWIST signaling pathways.
Role of the vasculature might be essential for liver
metastasis
Vermeulen et al. [117] reported that colorectal cancer
metastases to the liver grow according to three different
histologic patterns, termed ‘pushing’, ‘replacement’, and
‘desmoplastic’ growth patterns. The results of subse-
quent studies [118,119] involving liver metastases of
colorectal and breast cancers showed that the different
grow patterns have different angiogenic properties. The
replacement pattern grows by co-opting the stroma,
without induction of hypoxia or angiogenesis and thus
minimal perturbation of the liver architecture; however, the
pushing and desmoplastic patterns grow in an angio-
genic fashion, which is at least in part hypoxia-driven.
Furthermore, the pattern of replacement growth in a
non-angiogenic process is even more prevalent in breast
cancer than colorectal cancer, and the process induces
neither hypoxia nor vascular leakage.
Martin et al. [120] has shown that the majority of early
metastatic foci in the liver contain few cells, even 12 days
after breast cancer cell injection. Only a few foci were able
to develop into micrometastatic lesions with a patent
Figure 1 A model for breast cancer liver metastasis. (i) intravasation: invasive breast cancer cell invades through the endothelium of a tumor
blood vessel into circulation; (ii) circulation: breast cancer cell survives in the blood vessels without any attachment; (iii) margination: circulating
breast cancer cell arrests at the site of liver by adhering to the sinusoidal endothelial cell via specific sets of adhesion molecules; (iv) extravasation:
the migrated breast cancer cell invades through the endothelial wall of sinusoidal endothelial cell, migrates and finally proliferates in the liver;
and (v) colonization: breast cancer cells survive and form a life-threatening focus in liver.
Ma et al. Journal of Translational Medicine  (2015) 13:64 Page 6 of 10vasculature, thus suggesting that lesions that utilize
an existent patent blood supply can thrive in the liver
microenvironment, while the remaining foci without a
vascular supply remain dormant in the liver. Naumov et al.
[121] suggested that tumors are dependent on angiogenesis
for progressive growth and remain harmless to the organ-
ism at the non-angiogenic dormant stage. Furthermore, the
expansion of tumor mass is associated with recruiting
endothelial cells after the cancer tissues undergo a
switch from a non-angiogenic dormant phenotype to
the angiogenic phenotype [122].
Therefore, we speculate that breast cancer metastases
to the liver grow mainly by the replacement pattern with
a non-angiogenic process in the initial stage, and the
vasculature is crucial for thriving in the sites of liver
metastases in the late stage.
Role of sinusoidal capillaries
Previous studies have reported that the initial arrest of
cancer cells in the sinusoids of the liver is restricted
by the sizes of cancer cells [123,124]. Haier et al. [125] has
determined that tumor cells adhere to sinusoidal capillaries,
the internal diameter of which is larger than the tumor
cells. Unique structural features of liver, including the exist-
ence of a fenestrated endothelium (sinusoidal endothelium)
and lack of an organized sub-endothelial basement mem-
brane, have a great impact on the interactions betweenbreast cancer cells and the liver microenvironment. Of
great interest, the fenestrated endothelium controls liver-
specific microvascular exchange and impacts the ability of
cells to transmigrate through the vessels into the liver
[126]. Moreover, previous studies have revealed that breast
cancer cells extend cellular projections through the fenes-
trated endothelium into the space of Disse on seeding the
liver, which makes direct contact with hepatocytes [127].
In addition, Martin et al. [120] has found that breast
cancer cells are bound to vessels with clear vascular
labeling in the sites of liver metastases. Thus, sinusoidal
capillaries play a significant role in the initial arrest of
breast cancer.
Changes in hormonal receptor status and HER-2
ER, PR, and HER-2 status is essential in determining the
use and evaluating the effect of adjuvant hormone therapy,
molecular targeted therapy, and even chemotherapy.
Koo et al. [128] conducted a study to assess the status of
ER, PR, and HER-2 in primary and metastatic breast
cancers and determined the relationship between ER,
PR, and HER-2 and organ-specific metastases of breast
cancer. The data showed that ER+ or PR+/HER-2-
(luminal A) subtypes were predominant in the sites of
liver metastases (75.0%). Increased phosphorylation of
HER-2 appears to be extremely important for the estab-
lishment of breast cancer liver metastases [129]. Moreover,
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doubles the relative risk of progression and mortality [130].
Nevertheless, the ER, PR, and HER-2 status between
primary breast cancers and liver metastatic foci can be
changed after treatment, but are stable in most cases
during the liver metastatic process [131]. Botteri et al.
[132] conducted a retrospective study of patients with
BCLM and found a positive relationship between liver
biopsy findings and survival in patients with early
metastases. Moreover, another study showed that biopsies
of metastases are useful for the reassessment of the
metastatic sites to define a more effective treatment
strategy for patients with BCLM [133]. Thus, the ER, PR,
and HER-2 status needs to be reassessed by biopsy when
liver metastases occur.A model for breast cancer liver metastasis
An increasingly sophisticated understanding of breast
cancer liver metastasis is emerging. It appears that
BCLM is mainly associated with specific subtypes in
patients with breast cancer [85,86,92]; however, no
direct correlation between subtypes and BCLM has
been found. By combining the knowledge from the
extant research, we propose a model for breast cancer
liver metastasis (Figure 1), as follows: (i) intravasation:
invasive breast cancer cells invade via the endothelium of
a tumor blood vessel into the circulation; (ii) circulation:
breast cancer cells survive in the blood vessels and lack of
cell-cell or cell-matrix attachments; (iii) margination:
CTCs arrest at the liver site by adhering to the sinusoidal
endothelial cell via specific sets of adhesion molecules,
such as cadherins, integrins, Ig-SF, and CD44; (iv) extrava-
sation: the migrated breast cancer cells invade through the
endothelial wall of sinusoidal endothelial cells, migrates,
and finally proliferates in the liver (in this process, the
diameter of the sinusoidal endothelium and the lack of an
organized sub-endothelial basement membrane have a
great impact on breast cancer cell migration); and (v)
colonization: breast cancer cells survive and form a
life-threatening macrometastatic focus in the liver
microenvironment by mediating hypoxia-inducible factor-
regulated genes (LOX, OPN, VEGF, and TWIST), the
status of ER, PR, and HER-2 expression, and angiogenesis
for breast cancer cells.Conclusions
The process of BCLM includes several steps and is influ-
enced by various factors. Although major breakthroughs
have been achieved recently in understanding of BCLM,
no effective therapies have been developed. Further under-
standing of the roles of breast cancer cells and the liver
microenvironment will open a new window to guide future
work in clinical treatments.Abbreviations
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